International Society for the Advancement of Spine Surgery Policy 2020 Update—Minimally Invasive Surgical Sacroiliac Joint Fusion (for Chronic Sacroiliac Joint Pain): Coverage Indications, Limitations, and Medical Necessity

MORGAN LORIO, RICHARD KUBE and ALI ARAGHI

doi: https://doi.org/10.14444/7156
http://ijssurgery.com/content/14/6/860

This information is current as of November 27, 2023.

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://ijssurgery.com/alerts
MORGAN LORIO, MD, FACS,1 RICHARD KUBE, MD,2 ALI ARAGHI, DO3
1Advanced Orthopedics, Altamonte Springs, Florida, 2Prairie Spine & Pain Institute, Peoria, Illinois, 3The CORE Institute, Sun City West, Arizona

ABSTRACT

The index 2014 International Society for the Advancement of Spine Surgery Policy Statement—Minimally Invasive Surgical Sacroiliac Joint Fusion—was generated out of necessity to provide an International Classification of Diseases, Ninth Revision (ICD-9)-based background and emphasize tools to ensure correct diagnosis. A timely ICD-10-based 2016 update provided a granular threshold selection with improved level of evidence and a more robust and relevant database (Appendix Table A1). As procedures and treatment options have evolved, this 2020 update reviews and analyzes the expanding evidence base and provides guidance relating to differences between the lateral and dorsal surgical procedures for minimally invasive surgical sacroiliac joint fusion.

OVERVIEW OF SACROILIAC JOINT ANATOMY, PAIN ETIOLOGY AND EPIDEMIOLOGY, DIAGNOSIS, AND NONSURGICAL INTERVENTIONS

Anatomy and Innervation

The sacroiliac joints (SIJs) are diarthrodial articulations of the sacrum and ilium with a joint capsule, synovial membrane, and opposing articular surfaces covered in hyaline cartilage.1 The SIJ serves as the biomechanical mediator between the spine and pelvis.2,3 The subchondral bone, capsule, and surrounding ligaments of the SIJ are innervated by spinal nerves.4 The joint moves (allowing both translational motion and rotation of the sacrum on the ilium), albeit only a small amount. SIJ pain is not correlated to the amount of joint motion.5 SIJ dysfunction or pain may be associated with altered laxity or stiffness of the SIJ, with increased or decreased joint translations, a new joint position, and/or exaggerated or reduced joint compression.6 The SIJ complex consists of an anterior portion (the articular portion of the joint) and a posterior extra-articular portion made up of the interosseous and dorsal ligamentous structures. The anterior portion of the joint is innervated anteriorly via branches of the ventral rami of the spinal nerves and ultimately from branches of the gluteal nerves, the obturator nerve, and the lumbosacral trunks4,7–11 and posteriorly by the lateral branches of the S1–S3 dorsal rami and fibers of the L5 dorsal ramus in some cases.7,10–17 Pain from the SIJ complex may arise from the posterior extra-articular elements in addition to, or separate from, the intra-articular elements.18 Frequent sources of extra-articular pain are ligamentous and muscular injuries, and enthesopathy.19

SIJ Pain Etiology and Epidemiology

SIJ pain is an important cause of acute and chronic low back pain. In some studies, the proportion of chronic low back pain attributable to the SIJ is 15%–30%.20–24 SIJ dysfunction or pain is frequently (up to 40% in some studies) implicated in patients with new or ongoing low back pain after lumbar fusion.25–28 Lumbar fusion is likely a risk factor for SIJ pain as biomechanical studies have shown significant stress transfer from the lumbar spine to the SIJ after 1- and 2-level lumbar fusion.29 Adjacent-segment degeneration after lumbar fusion

of the joint is innervated anteriorly via branches of the ventral rami of the spinal nerves and ultimately from branches of the gluteal nerves, the obturator nerve, and the lumbosacral trunks4,7–11 and posteriorly by the lateral branches of the S1–S3 dorsal rami and fibers of the L5 dorsal ramus in some cases.7,10–17 Pain from the SIJ complex may arise from the posterior extra-articular elements in addition to, or separate from, the intra-articular elements.18 Frequent sources of extra-articular pain are ligamentous and muscular injuries, and enthesopathy.19

SIJ Pain Etiology and Epidemiology

SIJ pain is an important cause of acute and chronic low back pain. In some studies, the proportion of chronic low back pain attributable to the SIJ is 15%–30%.20–24 SIJ dysfunction or pain is frequently (up to 40% in some studies) implicated in patients with new or ongoing low back pain after lumbar fusion.25–28 Lumbar fusion is likely a risk factor for SIJ pain as biomechanical studies have shown significant stress transfer from the lumbar spine to the SIJ after 1- and 2-level lumbar fusion.29 Adjacent-segment degeneration after lumbar fusion
Several authors have documented the association of SIJ (the adjacent segment caudal to a lumbosacral fusion) pain with multilevel lumbar fusion. Unoki et al have shown increased incidence of postoperative SIJ pain with increased number of spinal levels fused. Sagittal alignment is also known to affect adjacent-segment degeneration after spinal fusion. Several authors have examined lumbar sagittal balance as a contributor to post–lumbar fusion SIJ pain suggesting that failure to restore lumbar lordosis (leaving the patient with a residual pelvic incidence–lumbar lordosis mismatch) is associated with post–lumbar fusion SIJ pain.

Impact of SIJ Pain

The spectrum of pain and disability from SIJ dysfunction is wide. Patients may be affected mildly or may have substantial functional impairment (eg, cannot sit or stand for more than 5 minutes, cannot perform normal activities of daily living, cannot walk up or down stairs, may require a wheelchair). Patients with chronic SIJ dysfunction seeking surgical treatment have marked impairment of quality of life (QOL), similar to that observed in other spinal conditions commonly treated surgically.

SIJ Pain Diagnosis

Convergence of the sensory pathway from the hip, the SIJ, and the lumbar spine may result in overlap of pain patterns from dysfunction of these structures. As such, proper SIJ pain diagnosis is key to appropriate patient management.

SIJ pain diagnosis is typically accomplished via a clinical diagnostic algorithm involving history, physical exam, diagnostic block, and ruling out other pain contributors. Patients with SIJ pain typically report pain in the buttock(s), with possible radiation into the groin or upper legs. Position and range of motion testing of the SIJ are not reliable. Specific physical examination tests that stress the SIJ (eg, distraction test, compression test, thigh thrust, Flexion Abduction External Rotation [FABER aka Patrick] test, Gaenslen maneuver) are typically performed in the physician’s office; in combination, these tests are thought to be predictive of a positive response to intra-articular SIJ block and likely indicative of SIJ pain. Other authors have presented conflicting data and results stating physical exam maneuvers to identify intra-articular SIJ pain did not demonstrate diagnostic value when compared with the reference standard of an intra-articular anesthetic block. With an increasing number of positive physical examination maneuvers, the diagnosis of SIJ pain is more likely. A recent systematic review determined there was significant evidence to constitute a clinical diagnostic rule for SIJ pain based upon 3 of 5 positive tests.

Imaging of the SIJ may be helpful in cases of inflammatory sacroiliitis and acute trauma. However, no specific imaging modality has demonstrated acceptable sensitivity and specificity in the diagnosis of noninflammatory, nontraumatic SIJ pain, including plain radiographs, computed tomography (CT), magnetic resonance imaging, and radionucleotide studies. In many cases, imaging may demonstrate nonspecific findings in the SIJ. Pelvic and spine imaging is used to ensure that the patient does not have alternative diagnoses that could mimic SIJ pain (eg, hip osteoarthritis, occasionally L5-S1 spine degeneration).

The diagnosis of SIJ pain is confirmed by performing an image-guided percutaneous intra-articular SIJ block with local anesthetic (eg, lidocaine). The SIJ has a large surface area but has a very small joint capacity which ranges from 0.8 to 2.5 mL in asymptomatic individuals, and from 1.0 to 2.5 mL in symptomatic individuals. It is generally advised to inject no more than 2.5 mL during an intra-articular diagnostic injection. Extravasation of injectate (local anesthetic) onto nearby neural structures theoretically compromises the specificity of the diagnostic injection. Periarticular SIJ block is not considered a reference standard for the diagnosis of pain coming from the articular SIJ. A periarticular block will likely anesthetize soft tissues in the dorsal aspect of the SIJ and sacrum. Pain arising from these soft tissues may or may not respond to surgical fusion of the SIJ. An acute reduction in typical pain following an intra-articular block indicates a positive test, suggesting that the injected joint is a pain generator. A study of patients undergoing blinded injection of saline or local anesthetic showed markedly high responses to the latter, validating the test.

Occasionally, bilateral SIJ pain can occur. Diagnosis of bilateral SIJ pain should be made on the basis of typical history (bilateral symptoms), physical examination showing positive responses to SIJ-stressing maneuvers bilaterally, and bilateral
acute pain relief upon bilateral, image-guided SIJ block.

**Higher Response to Diagnostic Block Does Not Predict Higher Response to Definitive Treatment**

While a marked response to SIJ block might reassure the physician that treatment will produce larger responses to anatomic-based intervention, published data suggest little, if any, relationship. In 2 large prospective clinical trials of lateral transiliac MIS SIJ fusion (SIJF) with transfixing devices, patients with suspected SIJ pain were included only if intra-articular SIJ block resulted in a 50% or greater acute pain relief within 60 minutes after the block. The amount of improvement at 12 and 24 months after SIJF was unrelated to the amount of acute pain relief during the block.\(^7\) In a retrospective analysis of predictors of outcome success after radiofrequency (RF) ablation of lateral branches of the sacral nerve roots in patients with SIJ pain, no relationship was observed between response to lateral branch block or SIJ anesthesia and response to RF ablation.\(^7\) Randomized trials of RF ablation of lateral branches of the sacral nerve roots excluded patients with <75% pain reduction after lateral-branch block (1 block in Cohen et al\(^7\) and 2 blocks in Patel et al\(^7\)), leaving open the question of whether the selected threshold was appropriate. Application of an overly stringent selection criteria (ie, 75% response) has no basis in evidence and is likely to result in the withholding of a beneficial procedure from a substantial number of patients with significant pain and functional impairment.\(^7\)

**Nonsurgical Treatment**

Multiple nonsurgical treatments for SIJ pain are available, including pain medications (eg, nonsteroidal anti-inflammatory drugs [NSAIDs]), physical therapy (PT), steroid injections into the SIJ, and RF ablation of the sacral nerves. NSAIDs in combination with icing and activity modification may be helpful in reducing pain in acute or subacute SIJ pain.\(^7\) However, NSAIDs have not been shown to impact the underlying disease process. Opioids have not been shown to be a safe and effective treatment for chronic SIJ pain and addiction remains an important public health concern.

The effectiveness of PT for treating chronic SIJ dysfunction and pain has not been demonstrated. There is a paucity of high-level literature secondary to the great variability in the functional biomechanical deficits in patients with SIJ pain, and that standard practice is to apply more than one form of treatment at a time. In addition, much of the literature evaluates patients with acute or subacute SIJ pain. A significant portion of this patient population would be expected to improve with time, with or without intervention. Generally, the approach to therapeutic exercise is linked to balancing muscle length, strength, and appropriate motor control in order to efficiently absorb and transmit force from the ilium to the sacrum.\(^7\) PT treatments (eg, exercise, manipulation) may provide benefit in some patients and are a reasonable option with few risks.\(^7\) It is reasonable to prescribe a short course (4–6 weeks) of individualized, supervised therapeutic exercises focused on strengthening of the core muscles (local stabilizers) progressing to strengthening of the global stabilizers as tolerated.\(^7\) Exercise programs should be individually tailored based on clinical findings, physical capacity, and anticipated compliance. It is not reasonable to continue with a therapeutic exercise program if it is painful for the patient or in cases where the patient fails to improve after a reasonable course of treatment (4–6 weeks).

Therapeutic exercise in SIJ pain patients is typically focused on core strengthening. One randomized, controlled trial (RCT) performed in peripartum women (acute and subacute SIJ pain onset during pregnancy or within 3 weeks of delivery) showed significant improvement in pain and function at 12 months. The therapy program consisted of an individualized, supervised program of stabilization exercises lasting 20 weeks.\(^8\) A second RCT in a similar patient population showed minimal improvement in pain or function with an 8-week program consisting of stabilization exercises that were not individualized and not supervised.\(^8\) A study comparing 4 weeks of therapeutic exercise to laser treatment in patients with acute and subacute SIJ pain (<3 months duration) showed improvements in pain and function at 12 months in the exercise group.\(^8\) Another small study (51 patients with SIJ-related leg pain [duration >4 weeks but less than 1 year] without confirmatory diagnostic block) compared therapeutic exercise (6 weeks) to manual PT and steroid injection.\(^8\) Only 20% of the patients in the PT cohort had improvement that met minimal clinically important difference (MCID) (2-point improvement on visual analog scale [VAS]) at 12 weeks. In the nonsurgical treatment cohorts of the
iFuse Implant System (SI-BONE, Inc) RCTs, the percentage of patients (all of whom were symptomatic for at least 6 months) that met MCID for pain improvement at 6 months were 24% in INSITE (Investigation of Sacroiliac Fusion Treatment)\(^8^4\) (mean number of PT visits: 14) and 22% in iMIA (iFuse Implant Minimally Invasive Arthrodesis)\(^8^5\) (mean number of PT visits: 26). In the large multicenter MINT (Cost-Effectiveness of Minimal Interventional Procedures for Patients with Chronic Low Back Pain) RCT, patients with chronic SIJ pain were randomized to PT (3-month standardized exercise program and psychological support if needed) versus RF ablation. Fifty-five percent of the PT group patients had at least a 2-point improvement on VAS compared to 58% of the RF ablation group at 12 months.\(^8^6\)

Manual medicine techniques (manual therapy, osteopathic manual treatment, chiropractic adjustments) are often part of the treatment of SIJ pain. Several poorly controlled studies of these treatments have demonstrated clinical improvement of SIJ pain.\(^8^7\)–\(^9^0\) In a recent review of PT interventions, Al-Subahi et al\(^9^1\) identified 4 studies that met inclusion criteria and concluded there is some evidence that SIJ manipulation may lead to improvements in pain and function. These studies suffered from small sample size, lack of a control group or use of an unproven treatment as a control, or from inclusion based upon unreliable physical examination tests.\(^9^2\)–\(^9^5\) SIJ bony asymmetries have been clinically shown in uncontrolled studies to resolve with manipulation.\(^9^0\)–\(^9^6\) SIJ position and range of motion testing has been shown in well-controlled studies to be unreliable.\(^4^4\)–\(^4^7\) Tullberg et al,\(^9^7\) using radio stereophotogrammetric analysis, showed no change in SIJ bony position after SIJ manipulation and Dreyfuss et al\(^9^5\) showed no significant correlation between “joint motion” and response to intra-articular injection of local anesthetic. If an SIJ appears to require recurrent joint mobilization, a significant muscle imbalance may still exist or the patient may have joint hypermobility as a result of conditions such as Ehlers-Danlos syndrome. Some of this may be related to patient compliance or an inadequate neuromotor control and strength-directed program, or may be related to the patient’s inherent collagen makeup that allows increased joint mobility and/or tissue laxity. Caution should be used with repetitive manipulation in the latter group.\(^7^7\) In spite of the low level of evidence to support manipulation and other manual treatments, the low risks of these interventions warrant consideration by trained professionals.\(^9^8\)

Intra-articular SIJ steroid injections are commonly provided interventions worldwide.\(^9^9\),\(^1^0^0\) There is no high-level evidence supporting the short- or long-term effectiveness of this treatment option. Three pragmatic RCTs of SIJ steroid injection randomized against radiofrequency (RF) ablation have been published.\(^1^0^1\)–\(^1^0^3\) None of these studies demonstrated improvement in pain or function beyond 1 month with injections. Another study of SIJ steroid injection versus prolotherapy showed no significant improvement in the steroid cohort beyond 2 weeks.\(^1^0^4\) In the absence of definitive data supporting corticosteroid injections as superior to placebo, the value of trials with corticosteroid injections as an active control group is questionable. Repeated steroid injections have shown association with accelerated cartilage degeneration in the hip and the knee.\(^1^0^5\),\(^1^0^6\) The cost-effectiveness of SIJ steroid injections has not been determined. No studies have demonstrated long-term pain relief, nor have studies confirmed the benefit of repeating this procedure multiple times. Other interventions to treat pain arising from the SIJ complex include prolotherapy and injection of platelet-rich plasma or other substances. There is no high-level literature to support these other interventions.

RF ablation is another commonly performed intervention to treat pain arising from the SIJ complex. Four explanatory randomized trials (RF ablation versus sham) have been published. Two studies showed that RF ablation of lateral branches of sacral nerve roots can temporarily reduce SIJ pain.\(^7^4\),\(^7^5\) One-year follow-up from one RF ablation randomized trial showed modest pain reduction.\(^1^0^7\) Mehta et al,\(^1^0^8\) in a small trial (n = 30) of RF ablation strip lesioning versus sham, showed significant improvement in VAS and EuroQOL-5D scores at 3 months. A more recent study of heated RF ablation versus sham demonstrated no significant difference in pain level or patient satisfaction at 1 or 3 months.\(^1^0^9\) There are 3 pragmatic RCTs of RF ablation randomized against SIJ steroid injection. Salman et al\(^1^0^1\) showed 53% of patients had at least 50% pain improvement with heated RF ablation at 6 months. Cánovas et al\(^1^0^3\) showed modest improvement (2 points on VAS at 12 months with bipolar palisade) and better results (4 points VAS improvement at 12 months) with a
modified bipolar palisade technique. In a small series (30 patients), Dutta et al\textsuperscript{102} showed improvement in VAS in the RF ablation group of 3.8 points at 6 months with pulsed RF ablation. In a much larger study of SIJ RF ablation randomized against PT, the authors demonstrated no significant differences in pain level or patient satisfaction at 3, 6, 9, or 12 months.\textsuperscript{86} RF ablation was not considered to be cost-effective from a societal perspective for patients with chronic pain originating from the SIJ in the Dutch healthcare setting.\textsuperscript{110} Interpretation of the RF ablation literature is limited by variability in patient selection criteria, the specific nerves targeted for ablation, and the types of RF ablation technology and technique utilized.\textsuperscript{18}

\textbf{COVERAGE RATIONALE FOR OPEN AND MIS SIJ FUSION}

Given the absence of published outcomes data supporting long-term pain relief from nonsurgical treatment, patients with a diagnosis of chronic SIJ pain who experience pain for a minimum of 6 months, and who do not respond to an appropriate course of nonsurgical treatment, may be considered for SIJF.

\textbf{Open SIJF Procedures}

Open fusion of the SIJ, first reported in the early 1900s,\textsuperscript{111} can provide pain relief but recovery times are long and complication rates may be high.\textsuperscript{112–117} Intraoperative times, bleeding, and hospital length of stay are more prominent compared to MIS SIJF,\textsuperscript{117–120} and recovery times are long and may require prolonged postoperative rehabilitation. The open surgical procedure, whether from an anterior, a posterior, or a lateral approach, requires a large incision (8 cm or greater) and extensive surgical dissection. Open procedures are associated with increased surgical time and correspondingly increased patient morbidity. In certain cases, such as acute trauma, tumor, infection, or for SIJF in conjunction with pelvic fixation in spinal deformity surgery, open SIJF is indicated.

\textbf{Anterior Approach}

The anterior surgical approach to the SIJ was described in 1941.\textsuperscript{121} The anterior approach to the SIJ for open reduction and internal fixation in cases of SIJ trauma was popularized in the 1980s.\textsuperscript{122,123} More recently, the anterior approach has been utilized for elective SIJF and several series have been reported.\textsuperscript{124–127} Most series describe a surgical approach that follows the anterior iliac crest deep to the iliacus muscle (subiliac approach). This approach is associated with significant morbidity including possible injuries to the vascular, gastrointestinal, and genitourinary structures, L5 nerve root, and lateral femoral cutaneous nerve. Postoperative hip flexor weakness has also been described.\textsuperscript{128} Murakami et al\textsuperscript{129} have described a para-rectus retroperitoneal anterior approach to the SIJ with less patient morbidity. After the joint is accessed, the anterior joint capsule is removed and the articular SIJ is debrided with a burr and curettes. The articular joint is bone-grafted and the joint is stabilized with a short plate and multiple screws. The size of the plate is limited by the local bony anatomy and close proximity of the L5 nerve root.

\textbf{Lateral Approach}

The lateral approach was described by Smith-Petersen and colleagues in the 1920s.\textsuperscript{130–132} In this approach, the gluteus musculature is elevated from the lateral aspect of the ilium and a bone window is created through the ilium providing access to the SIJ. The interosseous ligament and the articular cartilage are debrided, the joint is grafted and the bone window is replaced. Several variations of the procedure have been described.\textsuperscript{116,133,134} Concurrent permanent fixation of the SIJ with screws, either from lateral or posterior approach, is described by most authors.

\textbf{Posterior Approach}

The posterior approach to the SIJ was first described in 1908.\textsuperscript{111} Early reports described debridement of posterior soft tissues and grafting of the dorsal recess. Postoperatively the patient was placed into a hip spica cast for several months to immobilize the joint. As fixation methods improved, a variety of posterior fusion procedures were described including application of posterior bars and iliac plates.\textsuperscript{113,135} The most recent description of the open posterior procedure describes an osteotomy of the medial aspect of the posterior iliac crest to allow surgical access to the articular SIJ. This open procedure includes excision or debridement of the dorsal ligaments, dorsal joint capsule, interosseous ligament, and osteoclasis of the articular SIJ cartilaginous surfaces, which lie ventral to the ligamentous portion of the joint. Surgical access to these structures is not possible without an osteotomy of
the overlying iliac crest. Bone graft and spacers or cages are typically placed into the joint. The joint is then stabilized with fixation that includes a pedicle screw into the ilium, and a pedicle screw into the sacrum connected with a spinal rod.\(^{114,117}\)

Open posterior SIJF is frequently performed as part of long spinal deformity fusion procedures that include pelvic fixation (sacroalar iliac [S2AI] or iliac screws or bolts).\(^{136}\) As described below, SIJF has been proposed in response to concerns of implant failure and postoperative SIJ pain. Long spinal fusion with pelvic fixation is associated with an elevated risk of new-onset SIJ pain\(^{32,33,35,36}\) and increased incidence of SIJ pain and an increased incidence of SIJ pain is correlated with increased number of levels fused.\(^{37}\) Pelvic fixation with both S2AI and iliac screws is associated with a significant risk of screw loosening (0%–39%) and screw failure (0%–24%).\(^{137}\) Pelvic fixation likely alters the biomechanics of the SIJ but clinical implications have not been defined.\(^1\) Continued SIJ motion after pelvic fixation may contribute to screw loosening and/or failure\(^{138}\) and may also contribute to postoperative lower back pain.\(^{139}\) Screw loosening is common even with solid fusion at L5–S1, indicating that the SIJ remains mobile.\(^{140,141}\) S2AI screws have been shown to violate the articular cartilage of the SI joint in 40% of cases.\(^{142}\) Some surgeons now advocate for 2 points of fixation in conjunction with SIJF in pelvic fixation cases in order to minimize SIJ rotation.\(^{143–145}\) Recent biomechanical studies have shown that placement of titanium triangular implants (TTI) in conjunction with an S2AI screw decreases SIJ motion by 30% and lowers strain on the adjacent S1 and S2AI screws.\(^{146}\) This approach is currently under study.

**MIS SIJF Procedures**

MIS principles and techniques have been applied to SIJF. New devices allow stabilization and fusion of the SIJ with small incisions and minimal soft tissue damage. As with other MIS procedures, MIS SIJF has shown decreased operative time, decreased blood loss, and decreased hospital stay compared to the open procedure.\(^{117,119,120}\) SIJF is most commonly performed via an MIS procedure.\(^{147}\) Two different MIS SIJF procedures have been described.

**Lateral Transiliac MIS Procedure**

The lateral transiliac MIS procedure involves placement of devices that transfix the SIJ (ie, a device that traverses the ilium and the SIJ and ends in the sacrum). The surgical approach is from the lateral or posterolateral ilium with device placement through the ilium, across the SIJ, and into the sacrum. Approximately 25 devices are currently cleared by the US Food and Drug Administration (FDA) for this procedure\(^*\) and the FDA indication statement typically describes use in patients with chronic SIJ pain and/or disruption (eg, related to trauma or overuse) and degenerative sacroiliitis (osteoarthritic degeneration).

**Posterior (Dorsal) MIS Procedure**

The posterior (dorsal) MIS procedure involves placement of bone allograft products or devices into the ligamentous portion of the joint via dissection of the multifidus muscle and removal of a portion of the ligaments covering the outer posterior surface of the joint. The stabilization strategy with these products is ligamentotaxis and the fusion strategy is distraction arthrodesis. The majority of the products used for this procedure are unclassified allograft bone products (human cell and tissue products) and therefore do not carry an indication statement specific to SIJF. There are 2 FDA-cleared medical devices used for posterior MIS procedures: Catamaran SIJ Fixation System (Tenon Medical, Inc)\(^1\) and NADIA (Ilion Medical, Inc).\(^1\)

---


condition. Nearly all such procedures follow the lateral trajectory approach initially published by Routt et al.\textsuperscript{148} for use in iliosacral fixation to treat traumatic injuries of the posterior pelvic ring.

Several reports describe lateral SIJF using iliosacral fixation screws with supplemental bone grafting from posterior or lateral approaches.\textsuperscript{116,149} In the United Kingdom, Mohanty popularized lateral MIS SIJF using a cage filled with bone in an effort to avoid supplemental bone grafting and thus lessen the morbidity and cost of the procedure. Three different series describe use of a lateral approach with placement of these hollow modular anchor cages from Aesculap.\textsuperscript{150–152} (This device is not FDA-cleared for use in the United States for this indication.)

In 2008, SI-BONE, Inc, received FDA clearance to market a TTI with a porous surface for SIJF. Subsequent to this, at least 25 different lateral transiliac transfixing devices have received FDA clearance for lateral MIS SIJF.\textsuperscript{8} The clinical evidence base for use of these devices has grown substantially over the past decade; however, most high-level clinical evidence supporting the safety, effectiveness, durability, and economic benefit of lateral MIS SIJF is derived from use of iFuse. Physician work and resource utilization studies have been published on the lateral MIS SIJF procedure.\textsuperscript{153–155}

### Clinical Evidence

Clinical evidence for lateral transiliac MIS SIJF is now substantial and includes 2 RCTs and 5 multicenter prospective studies. These studies provide substantial evidence that lateral transiliac MIS SIJF with placement of lateral transfixing devices is safe and effective. Studies demonstrate consistent improvements in pain, function, and QOL. In both randomized trials, pain relief, disability reduction, and improvement in QOL were markedly higher in SIJF subjects compared to nonsurgically treated subjects. Results of lateral transiliac MIS SIJF with transfixing TTIs are consistent across patient populations and geographies, and preliminary data from non-TTI lateral transfixing devices appear to provide similar responses (Figure 1 and Figure 2).

### Level I Studies Summary

Two prospective, multicenter RCTs have yielded numerous (Level I) published studies evaluating lateral transiliac MIS SIJF using TTI (iFuse Implant System, SI-BONE, Inc). These studies demonstrate the immediate and sustained pain relief experienced by patients treated with lateral transiliac MIS SIJF.

**INSITE.** In the INSITE trial, a multicenter, prospective RCT conducted in the United States,\textsuperscript{156} subjects treated with iFuse had early (1 month) and sustained (24 months) improvement in pain and function. VAS SIJ pain improved from 82.3 to 26.1 (55.8 points, \( P < .0001 \)). Mean changes in the nonsurgical group were not clinically significant (mean 12 points by month 6) and many subjects crossed over to surgical treatment (which was successful in most cases). Similarly, in the SIJF group, mean Oswestry Disability Index (ODI) scores decreased from 57.2 to 28.5 (28.5 points, \( P < .0001 \)). The 6-month improvement in ODI in the nonsurgical group was 4.6 points (substantially less than the 15-point MCID threshold used in the study). Similar rapid and sustained clinically important improvements were seen in QOL measures (SF-36 PCS [Short Form-36 Physical Component Summary] and EuroQOL-5D [European Quality of Life Scale-Five Dimension]) in the surgical group. There was no statistical difference in number of adverse events per subject between the iFuse and the nonsurgical groups. There were 3 revision surgeries (3\%) within the 24-month follow-up.

**iMIA.** In iMIA, a multicenter, prospective RCT conducted in Europe,\textsuperscript{157} similar results were seen as in the INSITE trial. The 2-year results were published in *The Journal of Bone and Joint Surgery* in 2019. Mean VAS low back pain improvement was 45 points in subjects undergoing SIJF with iFuse implants and 11 points for those treated with conservative management (primarily PT). Disability scores (ODI) improved by a mean of 26 points in the surgical group versus 8 points in the conservative management group. Statistically significant and clinically important improvements were also documented in VAS leg pain, EQ-5D TTO, and Zung Depression score. Patient-reported improvement in

walking distance and improvement in work status were also documented.

**Level II Studies Summary**

Five prospective, multicenter (level II) studies evaluating lateral transiliac MIS SIJF using 3 different lateral transfixing devices have been published. These studies confirm the results of the level I studies in different practice settings, and confirm the homogeneity of the outcomes of the lateral transiliac MIS SIJF procedure.

**Sacroiliac Joint Fusion with iFuse Implant System (SIFI).** In SIFI, a prospective, multicenter trial conducted in the United States, 172 subjects underwent SIJF with TTI (iFuse Implant System). Mean SIJ pain improved from 79.8 to 26.0 at 24 months. Mean ODI improved from 55.2 to 30.9 at 24 months. The SIJ revision rate was 4.7% (8 subjects) by 24 months.

**Long Term Outcomes from INSITE and SIFI (LOIS).** In LOIS, subjects participating in the above-described SIFI and INSITE studies agreed to long-term follow-up. At year 5, improvements from baseline in pain, disability and QOL were durable. From baseline to 5 years there was a 54-point mean improvement in SIJ pain, a 26-point mean improvement in ODI, and a 0.29 (0–1 scale) improvement in EuroQOL-5D scores. There was no deterioration of results between year 2 and year 5. A total of 3 of 103 subjects (3%) had a surgical revision by 5 years. Independent radiographic analysis with thin-cut CT scans at 5 years demon-
strated bridging bone across the articular SIJ adjacent or distant to the implants in 85% of patients.

Study of Bone Growth in the Sacroiliac joint after Minimally Invasive Surgery with Titanium Implants (SALLY). In SALLY, a prospective multicenter clinical trial of a 3D-printed version of iFuse TTI (iFuse-3D), nearly identical improvements in pain, disability, and QOL were observed in 51 patients at 1 year after SIJF.\textsuperscript{160} ODI improved from 52.8 at baseline to 27.9 and SIJ pain improved from 78 preoperatively to 21 at 12 months (0–100 scale, $P = .0001$). There were 2 revision surgeries (3.9%): 1 revision to reposition a symptomatic malpositioned implant, and 1 revision after a motor vehicle...
accident. CT scans at 6 months and 1 year showed a high and increasing rate of bridging bone.

**Evolusion.** In Evolusion, a prospective, multicenter trial evaluating placement of the Simmetry implant (RTI Surgical), similar results were seen in the first 50 patients at 6 months’ follow-up.161 Clinical results of 50 patients at 24 months showed improvement in VAS back pain (75.2 to 30.1) and improvement in ODI (55.2 to 26.9). One revision surgery to treat a symptomatic malposition was reported.8

**SI-LOK Study.** Rappoport et al162 reported a prospective, multicenter trial of use of SI-LOK (Globus, Inc), a hydroxyapatite-coated screw, for SIJF in 32 subjects.162 VAS low back pain decreased from 55.8 at baseline to 28.5 at 12 months; ODI improved from 55.6 to 34.6. Two revision surgeries were reported in the first 12 months. Two-year results of 50 patients were recently presented. Improvements were noted in VAS back pain (30.1 points) and VAS leg pain (27.0 points) at 24 months.11

A pooled analysis of patient-level data from the 3 prospective trials of TTI (2 level I and 1 level II studies) was published in *Spine.*163 This analysis showed similar improvements in pain, function, and QOL across studies and geographies (United States and Europe). Among patients undergoing SIJF, smokers had slightly lower but still clinically important improvements in pain, disability, and QOL scores. Similarly, patients taking opioids at baseline had somewhat lower (but still clinically important) improvements. Of the 326 patients undergoing SIJF with these lateral transfixing devices, 1.2% (n = 4) had an early (<1 month) surgical revision and 2.8% (n = 9) had a late (>1 month) surgical revision. Large observed effect sizes suggest a true underlying treatment effect. The authors found no predictors of outcomes in the nonsurgical groups.

**Level III Studies**
Several comparative retrospective case series of lateral transiliac MIS SIJF have been published. In these studies, operative measures (duration of surgery, blood loss, length of stay) were lower in MIS SIJF with TTI compared to open anterior or open posterior SIJF procedures.117 Implant survivorship (ie, freedom from surgical revision) at 4 years was superior in patients undergoing SIJF with TTI versus those treated with iliosacral fixation screws.164 Vanaclocha et al165 reported superior outcomes of patients treated with TTI compared to both conservative care and RF ablation of the sacral nerve root branches out to 6 years. Finally, Claus et al166 reported a single-center experience using either cylindrical threaded implants (CTI) (Rialto, Medtronic, Inc), or TTI. Surgical time was slightly less with TTI compared to CTI. There was no significant difference in patient-reported outcomes for VAS back, VAS leg, ODI, or SF-12 at 6 or 12 months between the 2 cohorts. The revision rate for CTI was higher than for TTI (6.1% versus 2.4%, *P* = .11).

**Level IV Studies**
Several case series add to the literature supporting lateral transiliac MIS SIJF with placement of transfixing device(s).167–185 These studies demonstrate generally consistent results across device types within this group and among geographies. Long-term studies with 5–178 and 6-year165 follow-up were similar to results of a prospective 5-year study of iFuse.159

**Reviews**
Several reviews (narrative, systematic, and meta-analysis) have been published focusing on lateral transiliac MIS SIJF with transfixing devices.186–193 These reviews support the previously stated conclusions, including that lateral MIS SIJF is beneficial (proven improvements in pain and function) in appropriately selected patients with SIJ pain.

**Safety Studies**
**Complications.** The prospective clinical trials of lateral transiliac MIS SIJF consistently demonstrate
the safety and effectiveness of the approach. Adverse events in the clinical trials and in other studies have been consistently low (see Appendix Table A2). Schoell et al\textsuperscript{194} published an analysis of the Humana insurance claims database evaluating MIS SIJF for the time period 2007–2014. They reported an overall complication rate of 13.2\% at 90 days and a 16.4\% at 6 months. Most complications were wound and urinary tract infections (4.1\%). As described in the paper, the authors did not have access to individual patient records; it is likely that this type of analysis captured patients who did not have lateral transiliac MIS SIJF procedures and/or patients who had a complication that was unrelated to the SIJF procedure. Thus, these numbers are likely overstated.

**Revisions.** Surgical revision rates in prospective studies of TTI and other devices are relatively low, ranging from 1\%–5\%.\textsuperscript{157,158} SI-BONE, Inc (manufacturer of iFuse TTI) reported lower complication rates in an analysis of spontaneously reported events.\textsuperscript{195} The complaint rate of 3.8\% likely understates the true rate as all events are likely not captured through the described reporting mechanism. A second study focusing on implant survivorship showed a 96.5\% survivorship at 4 years in over 11 000 procedures performed in the United States.\textsuperscript{196} The 4-year cumulative revision rate (3.5\%) did not vary by age (\(<\)65 or \(\geq\)65) or sex. A third study by the same manufacturer compared survivorship between first-generation (11 070 cases) and second-generation (3D-printed, 3140 cases) TTI.\textsuperscript{197} There were no significant differences in complaints between the 2 generations of devices with an overall complaint rate of 1.3\%. The cumulative 1-year probability of revision was 1.5\% for the first-generation device and 1.0\% for the 3D-printed device (\(P = .0408\)).

**Biomechanical Studies**

Two recent reviews provide summary information on SIJ biomechanics and the effects of lateral transfixing devices.\textsuperscript{198,199} Several other studies have evaluated the effectiveness of specific lateral transfixing devices\textsuperscript{200–206} and have shown that these devices immediately stabilize the SIJ. Studies have shown that fusing the SIJ results in minimal stress transfer to adjacent joints. Lateral MIS SIJF results in minimal increase or decrease in motion or stress at the contralateral SIJ,\textsuperscript{207} minimal increase in motion at the L4–L5 or L5–S1 motion segment,\textsuperscript{208} and limited (5\%) increase in stress at the hip joint.\textsuperscript{209} The amount of stress transfer to adjacent segments after lateral transiliac SIJF is far less than the stress transfer to the SIJ after a lumbar fusion, namely a 52\% increase in SIJ motion after a L5–S1 fusion and 168\% after fusion from L4 to the sacrum.\textsuperscript{29}

**Economic Analyses**

**Cost-Effectiveness.** Multiple authors have evaluated the economic aspects of lateral transiliac MIS SIJF with joint-transfixing devices. In INSITE, the US-based randomized trial of TTI for lateral transiliac MIS SIJF, embedded healthcare utilization collection informed a Markov process cost-utility model, which showed a very modest incremental cost-effectiveness ratio of $13 300/QALY (Quality Adjusted Life Year) compared to nonsurgical treatment.\textsuperscript{210} SIJF with TTI was determined to be cost-effective in the short term and likely cost-saving in the longer term. The incremental cost-effectiveness ratio for lateral MIS SIJF with TTI ($13 300/QALY) is similar to that of hip ($10 000/QALY) and knee ($13 000/QALY) arthroplasty. Ackerman et al have shown the high cost and medical utilization in both the US Medicare\textsuperscript{211} and commercial payor populations.\textsuperscript{212} Publications by the same authors showed cost savings over time in both the Medicare\textsuperscript{213} and commercial payer\textsuperscript{214} populations when a patient is treated with lateral MIS SIJF versus continued nonsurgical management.

**Physician Work and Resource Utilization.** A retrospective comparative study utilizing Navicare data showed that operative time for lateral MIS SIJF Current Procedural Terminology (CPT) code 27279 was not statistically different from open microdiscectomy CPT 63030 (112 minutes versus 119 minutes (\(P = .135\))).\textsuperscript{154} Postoperative work was found to be greater for MIS SIJF than for open microdiscectomy. A work-intensity study comparing CPT 27279 to CPT 63030 showed preoperative, intraoperative, and postoperative workload for MIS SIJF with lateral transfixing device was higher than for open microdiscectomy CPT 63030.\textsuperscript{153} In 2015, the International Society for the Advancement of Spine Surgery (ISASS) conducted a study consisting of a Rasch analysis of 2 separate surveys of surgeons to assess work and assigned relative value units (RVU) for CPT 27279 MIS SIJF with a lateral
transfixing device.\textsuperscript{155} The regression analysis of the results of the 2 studies indicates a work RVU for CPT 27279 of 14.23.

**POSTERIOR (DORSAL) MIS PROCEDURES**

**Procedure Description**

The posterior (dorsal) MIS SIJF procedure is a recognized and well-described distinct surgical procedure.\textsuperscript{192,193,215} In the dorsal approach, allograft bone products or devices are placed into the ligamentous portion of the joint via dissection of the multifidus muscle and removal of a portion of the ligaments covering the dorsal, posterior aspect of the joint. A portion of the interosseous SIJ ligament is also typically removed.\textsuperscript{192,193,215}

The posterior (dorsal) MIS SIJF procedure is distinct from lateral transiliac MIS SIJF using transfixing devices (CPT code 27279) in several fundamental ways:

1. The surgical anatomy, being distinct, likely carries different risks that, to this point, are not well studied.
2. The surgeon’s work effort is distinct with the dorsal procedure requiring less surgical dissection, and the procedure generally taking much less time.
3. Initial stabilization is not achieved via transfixion with a laterally placed device, but rather by ligamentotaxis (tensioning of the ligaments supporting the SIJ via placement of a bone graft or device into the ligamentous SIJ).
4. Long-term stabilization or fusion is achieved via distraction arthrodesis rather than by integration of the surrounding bone of the ilium and sacrum into or onto the transfixing implants with eventual bridging bone across the SIJ adjacent to the implants. Distraction arthrodesis of the SIJ consists of placement of an implant or bone allograft into the ligamentous portion of the SIJ, thus “distracting the joint.” This places the supporting ligaments under tension, theoretically stabilizing the joint. Bone graft and/or recombinant human bone morphogenetic protein (rhBMP) are then utilized to achieve bone fusion. Distraction arthrodesis has also been described in the lumbar spine using stand-alone bone allograft\textsuperscript{216} and stand-alone fusion cages in the early 2000s.\textsuperscript{217,218} The results and clinical experience of ligamentotaxis and distraction arthrodesis are well described in the lumbar spine literature. These treatment strategies have fallen out of favor secondary to problems with both allografts (pseudarthrosis secondary to graft fracture or resorption) and cages (migration and subsidence, loss of lumbar lordosis, high pseudarthrosis rates, and the established need for supplemental spinal fixation\textsuperscript{219}). Currently, only 3 low-quality studies address the safety and effectiveness of MIS posterior SIJF with distraction arthrodesis.\textsuperscript{220–222}

There is no safety or effectiveness literature supporting the use of the latest generation of bone allograft products for posterior MIS SIJF.

5. The majority of the products (bone allograft) used in the dorsal MIS SIJF procedure are not medical devices cleared through the FDA Center for Devices and Radiological Health Premarket Notification process enumerated in section 510(k) of the federal Food, Drug, and Cosmetic Act. Rather, these allograft bone products are typically regulated through the FDA Center for Biologics Evaluation and Research, responsible for regulating human cell and tissue products. Certain human cell and tissue products are regulated under section 361 of the Food, Drug, and Cosmetic Act. These products must meet the criteria for “minimally manipulated tissue” outlined in 21 CFR 1271.109(a) and are not required to be licensed, cleared or approved by the FDA. No equivalence testing is required, and these are unclassified products per FDA regulations. Their labeling must reflect the manufacturer’s intent that they be used only for homologous use (nonspecific to any product claim).

6. The level of support in the clinical literature for the posterior (dorsal) MIS SIJF procedure is far lower than for the lateral MIS SIJF procedure.

Due to these differences, data from studies of lateral MIS transiliac SIJF with transfixing devices are likely not generalizable to these posterior (dorsal) MIS SIJF procedures.
Clinical Evidence

There is limited published clinical evidence supporting the safety and effectiveness of posterior (dorsal) MIS SIJF. There is 1 prospective multicenter study, no comparative studies, and only a small number of case series. All published studies describe placement of bone grafts or devices within the ligamentous SIJ.

Fibular Allograft

McGuire et al published the results of a retrospective series of 37 patients where fibular strut allografts were placed dorsally into the SIJ. Results presented in this paper are likely not generalizable to the current posterior MIS SIJF procedure performed with allograft products. This is primarily due to the procedure being studied. While labeled as MIS by the authors, the procedure included a large incision over the posterior iliac crest with subperiosteal exposure of the medial and lateral aspects of the posterior crest. Authors then performed an osteotomy of the posterior iliac crest to gain access to the articular SIJ after debridement of the interosseous ligament. These steps are not typical of the procedural steps described for current posterior (dorsal) MIS SIJF with contemporary allograft products or devices. These steps would be more typical of an open posterior SIJF procedure. Autograft from the osteotomized iliac crest was placed into the articular joint and the fibular struts were placed from the dorsal aspect of the joint across the debrided ligamentous portion of the joint to the ventral articular portion of the SIJ. It is not possible to access the articular SIJ from this trajectory without an osteotomy of the overlying iliac crest. The fibular struts were greater than 10–12 mm in diameter and were several centimeters in length. Autogenous bone grafting of the dorsal sacrum and adjacent ilium bones was also part of this procedure. The results of the procedure showed, at 52 months (range 24–62), improvement in VAS of 4 points, and a fusion rate of 89%. There were 4 (11%) nonunions treated with open revision fusion.

The current posterior MIS SIJF procedure and products differ greatly from that described by McGuire et al. The current graft products used in the dorsal procedure are much smaller than the fibular grafts. They are placed into a different portion of the joint (primarily into the ligamentous portion of the joint). These procedures are not considered to be “open” procedures, and are performed with no osteotomy of the iliac crest and no debridement of the dorsal or interosseous ligaments. They are typically performed without autogenous bone grafting of the articular joint, the dorsum of the sacrum, and the medial ilium. These newer allograft products are placed through a small incision(s) in a true MIS or even percutaneous manner. The physician work, length of surgical procedure, and resource utilization are much less with the newer products and the MIS dorsal procedure.

Fusion Cages

One FDA-cleared medical device for posterior MIS SIJF (NADIA, Ilion Medical, Inc) employs similar stabilization (ligamentotaxis) and fusion (distraction arthrodesis) strategies. NADIA is an iteration of the DIANA fusion cage (Signus, available only in Europe). No published studies document the safety and effectiveness of NADIA. A small retrospective case series reported 13-month results in 19 patients treated with the DIANA cage. Improvement from baseline to final follow-up in pain scores (8.5 to 6) and disability (ODI, 64 to 57) appears to be less than that observed with other approaches or devices. Estimated blood loss was less than 150 mL in all cases and length of stay was 7.3 days. Bone fusion described as bridging bone across the SIJ and absence of loosening around the implant was present in 79% of patients. A prospective, multicenter cohort using the same device in 171 patients showed somewhat larger 2-year improvements in SIJ pain (74 to 37) and ODI (51 to 33). Bone fusion described as bridging bone across the SIJ as evaluated on CT scan at 2 years was present in 31% of patients. This is less than bridging bone fusion of lateral transiliac MIS approaches with lateral transfixing devices shown in prospective trials of TTI (51% at 2 years and 85% at 5 years). Other reports of posterior MIS SIJF with distraction arthrodesis using cylindrical threaded cages filled with bone morphogenetic protein have cited higher fusion rates. Wise and Dall reported a prospective series of 13 patients treated with threaded fusion cages and rhBMP (notably, neither device is FDA-cleared for SIJF). VAS low back pain improved 4.9 points and VAS leg pain improved 2.8 points. There was 1 revision surgery for symptom-
atic pseudarthrosis. The fusion rate assessed on CT at 6 months was 79%. Other reported series also reported a higher fusion rate with use of rhBMP. Stark et al223 presented a series of SIJF cases using the DIANA cage with rhBMP reporting a fusion rate of 92%. Freeman reported a fusion rate of 89% at 24 months in a series of 38 patients undergoing SIJF using DIANA cages and rhBMP, many performed in conjunction with concurrent instrumented lumbar fusion.††

One additional device (Catamaran SIJ Fixation System, Tenon Medical, Inc) is FDA-cleared for MIS SIJF using a posterior approach. Rather than relying on ligamentotaxis and distraction arthrodesis, this device is placed across the posterior aspect of the inferior limb of the articular SIJ with one “outrigger” placed into the ilium and one into the sacrum. A scaffold connects the 2 outriggers. Biomechanical studies suggest that SIJ stabilization relies on lateral transfixion and avoiding disruption of the posterior interosseus and dorsal SIJ ligaments.203 Several other biomechanical studies have shown the effectiveness of various lateral transfixing devices for stabilizing the SIJ.200–202,204–207 As the Catamaran device is placed perpendicular to the axis of rotation (as opposed to placement parallel to the axis of rotation), the device does not engage the dense bone of the lateral iliac cortex. No biomechanical or clinical studies, to date, provide supportive evidence for this device.

LITERATURE SEARCH

A literature search was performed using the terms “sacroiliac joint” and “fusion or arthrodesis” and the PubMed interface to Medline; 439 hits were identified and abstracts reviewed. Relevant articles describing clinical results reported in prospective trials, retrospective case series, case reports and review articles are presented in Appendix, Table A2. See Appendix, Figure A1, Literature Search Exclusions Flow Chart, for the literature search strategy. Further numeric analysis was performed as follows.

For each article reporting either a case series or prospective study, data were abstracted for n, mean and SD of SIJ pain scores and ODI at both baseline and final follow-up. Change scores (from baseline to last follow-up) were also collected. Where sample sizes at final follow-up were low due to incomplete follow-up, an earlier time point was selected. Some articles did not report some SD values. Missing SD values were imputed conservatively using values derived from graphical analysis of SD as a function of study sample size. Data were entered into Excel and analyzed using R and the metafor package.‡‡ Each plot shows the mean observed value and 95% confidence limits per study at baseline and last follow-up (VAS pain: Figure 1 and Figure 2) or the mean change from baseline and last follow-up and 95% confidence limits (ODI: Figure 3 and Figure 4). Summary values with 95% confidence limits derived from random effects meta-analysis are shown at the bottom of each panel. Random effects meta-regression was performed comparing score improvements across surgical approaches (lateral transiliac versus posterior).

Numeric Synthesis

Meta-analysis was performed; graphical results are provided below.

SIJ pain scores were consistently and substantially lower at follow-up compared to baseline across studies and surgical approaches. Meta-analytic summaries showed similar baseline pain scores across procedure types but slightly lower scores at follow-up in studies using devices placed by a lateral transiliac approach (Figure 1). Score improvements were slightly larger for lateral transiliac studies (by 1.2 points [0–10 scale], P = .1497, Figure 3). There were some differences in outcomes between the lateral transfixing devices. Rialto and hydroxyapatite-coated screws appeared to show smaller changes.

For ODI scores, a similar pattern was observed with substantially lower scores at follow-up compared to baseline across studies. Final follow-up ODI scores appeared lower (better) for the lateral transiliac procedure; see Figure 2. ODI improvement from baseline was slightly larger (by 12 points, P = .1722) in studies using the lateral transiliac


approach compared to the posterior approach. Analysis was limited by the small number of studies reporting score improvements after the posterior procedure. For the lateral transfixing devices, the only published Rialto study showed smaller ODI improvements (but changes in the TTI group in the same study were also relatively small).

**INDICATIONS AND LIMITATIONS OF COVERAGE**

Patients who have all of the following criteria may be eligible for lateral transiliac MIS SIJF with placement of lateral transfixing devices:

- Chronic SIJ pain (pain lasting at least 6 months).
- Significant SIJ pain that impacts QOL or significantly limits activities of daily living.
- SIJ pain confirmed with at least 3 physical examination maneuvers that stress the SIJ (see list provided above) and reproduce the patient’s typical pain.
- Confirmation of the SIJ as a pain generator with $\geq 50\%$ acute decrease in pain upon fluoroscopically guided diagnostic intra-articular SIJ block using a small volume ($\leq 2.5$ mL) of local anesthetic. Prospective trials have shown that patients with SIJ pain responses of

![Figure 3. Baseline (blue) and last follow-up (green) ODI scores in cohorts of patients treated with lateral transiliac (LTI) sacroiliac joint fusion (SIJF) or posterior SIJF. Two studies did not report baseline ODI scores. Device type shown by shape. Horizontal bars denote confidence limit.](http://ijssurgery.com/)

Downloaded from [http://ijssurgery.com/](http://ijssurgery.com/) by guest on November 27, 2023
50%–75% respond to MIS SIJF as well as those with 75%–100% acute responses.\textsuperscript{72}

- Failure to respond to nonsurgical treatment consisting of NSAIDs and a reasonable course (4–6 weeks) of PT. Failure to respond means continued pain that interferes with activities of daily living and/or results in functional disability.

- Intra-articular SIJ steroid injection may be considered but is not required as there is no high-quality evidence supporting the safety and effectiveness of this intervention and there are potential risks and significant costs associated with this intervention. Treatment with repeat intra-articular steroid injection is not recommended.

- RF ablation of SIJ lateral branch nerves may be considered but is not required as there is only modest evidence supporting the safety and effectiveness of the procedure. There are currently no standardized patient selection algorithms, no standardized technology, and no standardized techniques. There are significant costs associated with the procedure. Treatment with repeat SIJ RF ablation is not recommended.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{oswestry.png}
\caption{Change in Oswestry Disability Index by study for devices placed by lateral transiliac (LTI) procedure and posterior procedure. Larger positive values mean more improvement. Device type shown by shape. Horizontal bracketed bars denote confidence limit.}
\end{figure}
Additional or alternative diagnoses that could be responsible for the patient’s ongoing pain or disability have been considered. Physicians should consider that patients can have multiple pain generators and addressing just one pain generator may not relieve all disability or all back pain.

**MIS SIJF is not indicated** for patients with the following:

- Less than 6 months of SIJ pain and/or functional impairment.
- Failure to pursue conservative treatment of the SIJ (unless contraindicated).
- Pain not confirmed with a diagnostic SIJ block.
- Presence of other pathology that would substantially prevent the patient from deriving benefit from SIJF.

**MIS posterior (dorsal) SIJF** is not recommended.

Bilateral SIJ pain is not uncommon. Diagnosis of bilateral SIJ pain must be made on the basis of a history of bilateral pain, bilateral elicitation of pain on physical examination maneuvers that stress each SIJ, and acute bilateral decrease in pain upon fluoroscopically guided intra-articular SIJ block with local anesthetic. Bilateral SIJF is probably best performed serially as successful treatment of one side may improve pain/disability to a degree acceptable to the patient. SIJF of the contralateral side may be necessary if contralateral SIJ pain continues and disability is significant for the patient. If bilateral fusion is performed at the same operative session, the surgeon must document both medical necessity and why serial fusion is not indicated in the patient.

It is expected that a person would not undergo more than 1 SIJF per side per lifetime except in the rare case that a revision is needed.

**CODING**

**Open SIJF**

The American Medical Association (AMA) recommends open SIJF be coded using CPT code 27280. Open SIJF may be performed from an anterior, posterior, or lateral transiliac (Smith-Petersen) approach, and all are appropriately reported via CPT 27280. The February 2014 AMA CPT Panel meeting revised CPT 27280 to include the word “open” and in addition to the anterior subiliacus approach found within the vignette, clarified further an anterior retroperitoneal approach. A second vignette describing a lateral transiliac (Smith-Petersen) approach was added. The open procedure, regardless of approach (anterior, lateral, posterior) includes extensive surgical dissection and access to the SIJ that allows visualization and excision of the dorsal and intraosseous ligaments in the posterior approach, excision of the intraosseous ligament in the lateral approach, and excision of the anterior joint capsule in an anterior approach with osteoclasis and grafting of the articular SIJ as a procedural component in all 3 approaches. Use of stabilizing fixation is typically performed in all 3 approaches. Fixation (regardless of type) is included as part of 27280. The American Medical Association (AMA) relative value scale (RVS) Update Committee (RUC) assigned intra-service time for the open procedure of 120 minutes; additionally, 2 postoperative in-hospital evaluation and management visits are associated with this code.

**Lateral Transiliac MIS SIJF**

The AMA recommends minimally invasive lateral transiliac SIJF with transfixing devices be coded using CPT code 27279. CPT 27279 includes bone grafting when performed and placement of transfixing devices. For bilateral procedures, report 27279 with modifier -50.

**Posterior (Dorsal) MIS SIJF**

Minimally invasive posterior (dorsal) SIJF should be coded using 22899 (unlisted procedure, spine) or 27299 (unlisted procedure, pelvis or hip joint). This includes placement of any device or product type which does not involve placement of a lateral transiliac transfixing device extending through the ilium, across the SIJ, and into the sacrum.

**Hybrid: Lateral MIS with Dorsal Placement of Bone Graft**

Procedures utilizing an MIS trajectory for placement of lateral transiliac transfixing devices, as well as for posterior placement of bone graft or other devices or products secondary to the primary (lateral MIS) procedure, should consider the primary CPT code for lateral MIS SIJF procedures (CPT 27279). Add-on CPT coding may be appropriate to report the addition of structural or osteopromotive...
bone allograft material placed posterior (dorsal) into the SIJ (eg, +20930, +20931).

Surgeons performing an open approach to the SIJ with associated surgical dissection to perform excision of the dorsal and interosseous ligament tissue and osteoclasis and grafting of the articular joint should consider CPT 27280 as well as any add-on CPT coding that may be appropriate to report services or procedures performed.

SIJF in Conjunction with Multi-Segment Spinal Fusion (Including Pelvic Fixation)

Pelvic fixation (eg, rods and connectors in a Galveston technique configuration) is commonly reported with add-on CPT code 22848. This may include placement of bolts and screws to fixate the pelvis. This may also be performed in conjunction with open or MIS SIJF, reported via CPT codes 27280 or 27279, respectively. TTI s (iFuse Implant System, SI-BONE, Inc) and some other devices are FDA-cleared to augment immobilization and stabilization of the SIJ as part of a lumbar or thoracolumbar fusion involving pelvic fixation.

Revision/Removal Procedures

Revision and/or removal of the SIJ implant would typically be coded using 22899 (unlisted procedure, spine) or 27299 (unlisted procedure, pelvis or hip joint) depending on the type of approach and procedure performed, whether within the global period of the fusion, or not.

DOCUMENTATION REQUIREMENTS

- A complete history and physical documenting the likely existence of SIJ pain
- Performance of a fluoroscopically-guided intra-articular SIJ block on the affected side (or both sides, see discussion above) which shows at least a 50% acute reduction in pain
- A course of conservative treatment to include use of NSAIDs and one of the following: (1) an adequate period of rest and activity modification, (2) an adequate course of physical therapy wherein the physical therapist specifically documents lack of response to treatment
- SIJ pain has continued for a minimum of 6 months
- Other diagnoses that could be causing the patient’s pain have been considered and the physician believes that SIJF is clinically required

SURGEON QUALIFICATIONS

- MIS SIJF is a surgical procedure performed by orthopedic or neurologic surgeons who have successfully completed a residency in that specialty as well as at least 1 specialized training course in the procedure. Training should include device placement in cadavers or other anatomic training models under supervision of a surgeon experienced in the procedure.
- Surgeons performing MIS SIJF should be specifically credentialed and/or privileged by at least 1 hospital to perform the procedure.

COVERAGE/CONCLUSION

Lateral MIS transiliac procedures for SIJF have become a recognized safe, predictable, and preferred surgical method for the management of intractable, debilitating primary or secondary SIJ pain disorders. The lateral procedure should be coded with CPT code 27279. The posterior (dorsal) MIS SIJF procedure is significantly distinct from the lateral procedure and is, as of yet, unproven. The posterior MIS procedure, regardless of device or product, should be coded with an unlisted procedure code.

The ISASS policy does not endorse any specific MIS SIJ system. There are numerous devices available that have received FDA 510(k) clearance for use in MIS or percutaneous lateral SIJF stabilization. The instrumentation utilized in a MIS SIJ procedure is the purview of surgeon preference.

REFERENCES

4. Szadek KM, Hoogland PV, Zuurmond WW, de Lange JJ, Perez RS. Nociceptive nerve fibers in the sacroiliac joint in


43. Cher DJ, Reckling WC. Quality of life in preoperative patients with sacroiliac joint dysfunction is at least as depressed as in other lumbar spinal conditions. *Med Devices Evid Res.* 2015;8:395–403. doi:10.2147/MDER.S92070


72. Polly D, Cher D, Whang PG, Frank C, Sembrano J, for


102. Dutta K, Dey S, Bhattacharyya P, Agarwal S, Dev P. Comparison of efficacy of lateral branch pulsed radiofrequency


194. Schoell B, Buser Z, Jakoi A, et al. Postoperative...


APPENDIX

Table A1. ICD-10-CM diagnosis codes and descriptions.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Code Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>M46.1</td>
<td>Sacroiliitis, not elsewhere classified</td>
</tr>
<tr>
<td>M53.2x8</td>
<td>Spinal instabilities, sacral and sacrococcygeal region</td>
</tr>
<tr>
<td>M53.3</td>
<td>Disorders of sacrum</td>
</tr>
<tr>
<td>S33.2xxA</td>
<td>Dislocation of sacral and sacrococcygeal joint</td>
</tr>
<tr>
<td>S33.6xxA</td>
<td>Sprain of sacral joint</td>
</tr>
<tr>
<td>099.89</td>
<td>Other specified diseases and conditions complicating pregnancy, childbirth, and the puerperium</td>
</tr>
<tr>
<td>094</td>
<td>Sequela of complication of pregnancy, childbirth, and the puerperium</td>
</tr>
</tbody>
</table>

Table A2. Published literature on minimally invasive surgical sacroiliac joint fusion. Inclusion criteria included the following: indexed in PubMed, English language, fusion of the sacroiliac joint described as minimally invasive surgery or percutaneous, and clinical outcomes available. Exclusion criteria included single-patient case reports, imaging studies, and technique reports with no clinical outcomes are excluded. The table also excludes Mao et al,182 as this article was simply an evaluation of the Oswestry Disability Index as an outcome measure, and the following 8 articles because they are narratives, systematic reviews, or meta-analyses: Shamrock et al,191 Whelan and Duhon,190 Tran et al,188 Zaidi et al,189 Heiney et al,186 Lingutla et al,187 Yson et al,192 and Martin et al.193

<table>
<thead>
<tr>
<th>Author and Year</th>
<th>Study Design</th>
<th>N</th>
<th>Level of Evidence</th>
<th>Follow-Up, mo</th>
<th>Implant Type</th>
<th>Technique</th>
<th>BMP, DBM, Graft Used</th>
<th>Demographics</th>
<th>Results</th>
<th>Complications</th>
<th>Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengler et al</td>
<td>Prospective, multicenter, RCT (n = 52 iFuse, n = 51 CM) 2-y results</td>
<td>103</td>
<td>I</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>NSM (n = 51) Age: 46.7 y (23-69 y) Female: 37 (72.5%) Pain duration: 4.5 y (0.45–23 y) BMI (kg/m²) 27.6 (16-44) SHF (n = 52) Age: 49.4 y (27-70 y) 0.210 Female: 73.1% 0.999 Pain duration: 4.9 y (0.58–44 y) BMI 26.5 (18-42)</td>
<td>VAS improved by 45 points (37-54 points) after SHF and 11 points (2-20 points) after CM, with a mean difference between groups of 34 points; ODI improved by 26 points (21-32 points) after SHF and 8 points (2-14 points) after CM with a mean difference between groups of 18 points. EQ-5D at 6 mo (0.37 point) and 24 months (0.39 point) and smaller changes in the CM group at 6 mo (0.09 point) and 24 mo (0.15 point). The mean Zung Depression Scale score showed no improvement in the CM group and a 5.3-point improvement in SHF group at 6 mo, and at 24 mo.</td>
<td>Within first 200 d, 20 AEs in the iFuse group and 17 AEs in the conservative group. No difference in rate between groups (p = 0.664) By 24 months, 39 severe events in iFuse group 4 related to study device or procedure. In conservative group, 27 severe events 1 related to a study procedure.</td>
<td>3.8% (2 of 52 iFuse patients within 2 y)</td>
</tr>
<tr>
<td>Dengler et al 2017</td>
<td>1-y, prospective, multicenter randomized controlled trial</td>
<td>103</td>
<td>I</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>NSM (n = 51) Age: 46.7 y (23-69 y) Female: 37 (72.5%) Pain duration: 4.5 y (0.45–23 y) BMI (kg/m²) 27.6 (16-44) SHF (n = 52) Age: 49.4 y (27-70 y) Female: 73.1% Pain duration: 4.9 y (0.58–44 y) BMI 26.5 (18-42)</td>
<td>VAS: At 6 mo, mean LBP improved by 43.3 points in SHF group vs. 5.7 points in the CM group. ODI in the SHF group improved from 57.5 points at baseline to 32.1 points at month 12. EQ-5D TTO improved from 0.35 to 0.74 EQ-5D VAS improved from 48.1 to 53.5 Zung Depression Scale improved from 45.7 to 39.6 at month 12.</td>
<td>Two SHF patients had recurrent pain attributed to possible device loosening and one had postoperative hematoma. In the CM group, 1 crossover patient had recurrent pain requiring a revision surgery.</td>
<td>1 revision</td>
</tr>
<tr>
<td>Sturesson et al 2017</td>
<td>Prospective, multicenter, RCT (n = 52 iFuse, n = 51 CM) 6-mo results</td>
<td>103</td>
<td>I</td>
<td>6</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>NSM (n = 51) Age: 46.7 y (23-69 y) Female: 37 (72.5%) Pain duration: 4.5 y (0.45–23 y) BMI (kg/m²) 27.6 (16-44) SHF (n = 52) Age: 49.4 y (27-70 y) 0.210 Female: 73.1% 0.999 Pain duration: 4.9 y (0.58–44 y) BMI 26.5 (18-42)</td>
<td>VAS: At 6 mo, mean LBP improved by 43.3 points in SHF group and 5.7 points in the CM group (difference of 38.1 points). ODI improved by 26 points in the SHF group and 6 points in CM group. EQ-5D changes of 0.15-0.46 reported</td>
<td>2 procedure-related AEs</td>
<td>0 revisions</td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>N</td>
<td>Follow-Up, mo</td>
<td>Implant Type</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
<td>Revisions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>---</td>
<td>---------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>--------------</td>
<td>--------</td>
<td>--------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dengler et al 2017&lt;sup&gt;23&lt;/sup&gt;</td>
<td>2-y, pooled patient-level analysis of 2 multicenter RCTs and 1 multicenter single-arm prospective trial</td>
<td>423</td>
<td>I</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean (SD) age: 50.4 (11.2) y Female: 70.4% Pain duration: averaged 5.5 y (SD 6.7, table 2). Mean baseline SJ pain: 80 points (SD 12.5) and ODI scores, 56 points (SD 12.7) were high QOL was diminished (mean EQ-5D index TTO: 0.43, (SD 0.20) and mean SF-36 PCS:31 (SD 5.9)</td>
<td>VAS 37.9 points larger in the SIJF group than in the NSM group. ODI 18.3 points larger. In NSM, no predictors of outcome. EQ-5D TTO index was 0.24 points larger for SIJF vs NSM. Signs of wound infection occurred in 8 subjects overall, including deep wound infection requiring surgical washout (n = 1), drainage from wound treated with antibiotics (n = 3), redness treated with antibiotics (n = 3), and slow healing treated with antibiotics (n = 1)</td>
<td>Of the 326 patients undergoing SIJF, 1.2% (n = 4) underwent early surgical revision. Late revision surgery (≥1 mo), performed in 2.8% (n = 9)</td>
<td></td>
</tr>
<tr>
<td>Polly et al 2016&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Prospective, multicenter, RCT 2-y results</td>
<td>148: 102 SIJF, 46 NSM</td>
<td>I</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 51.3 y; 12.2% (n = 18) were 65 y or older. 95.3% Caucasian 103 (69.6%) female Subjects were highly debilitated by SIJ pain as indicated by high baseline pain ratings (mean 82.3 on the 0–100 scale) and ODI scores (mean 56.8).</td>
<td>VAS improvement of 55.4 points at month 24. 83.1% and 82.0% received either clinical improvement or substantial clinical benefit in VAS SIJ pain score. ODI decreased from 57.2 at baseline to 28.1 at month 12 (improvement, 27.4 and 29.3 points, respectively. EQ-5D = 0.28 at 24 mo SF-36 = 11.2 points at 24 mo</td>
<td>Within first 180 d: 1.5 per iFuse subject 1.3 per NSM subject</td>
<td>3% (3 of 102 iFuse patients within 2 y)</td>
</tr>
<tr>
<td>Polly et al 2015&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Prospective, multicenter, RCT 12-mo results</td>
<td>148: 102 SIJF, 46 NSM</td>
<td>I</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 51.3 y; 12.2% (18 subjects) were 65 years of age 94.6% white 103 (69.6%) female Subjects were highly debilitated by SIJ pain as indicated by high baseline pain ratings (mean 82.3 on the 0–100 scale) and ODI scores (mean 56.8)</td>
<td>VAS = 28.3 at the 12-mo follow-up (54.2-point improvement). ODI decreased from 57.2 at baseline to 28.1 at month 12 (improvement, 27.4 and 29.3 points, respectively. EQ-5D = improvement of 0.74 (0.20 points) SF-36 = 43.1 (10.3 points)</td>
<td>12 mo of follow-up, a total of 42 severe AEs occurred</td>
<td>1 revision</td>
</tr>
<tr>
<td>Whang et al 2015&lt;sup&gt;48&lt;/sup&gt;</td>
<td>Prospective, multicenter, RCT 6-mo results</td>
<td>148: 102 SIJF, 46 NSM</td>
<td>I</td>
<td>6</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 51 y and 18 (12.2%) were 65 y or older. 94.6% Caucasian Approximately two-thirds female Subjects were highly debilitated by SIJ pain as indicated by high baseline pain ratings (mean 82.3 on the 0–100 scale) and ODI scores (mean 61.9)</td>
<td>6-mo follow-up was obtained in 97.3%. By 6 mo, success rates were 81.4% in the surgical group vs 23.9% in the NSM group. ODI improvement at 6 mo occurred in 75% of surgery subjects vs 27.3% of NSM subjects. At 6 mo. QOL improved more in the surgery group and satisfaction rates were high.</td>
<td>At 6-mo follow-up, 181 AEs were reported (133 in the surgery group and 48 in the NSM group). The mean number of events per subject was slightly higher in the surgery group (1.3 vs 1.0 events, P = .057).</td>
<td>1 revision: implant-related impingement on a sacral nerve root requiring immediate revision</td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>N</td>
<td>Follow-Up, mo</td>
<td>Implant Type</td>
<td>Technique</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
<td>Revisions</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>---</td>
<td>---------------</td>
<td>--------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Whang et al 2019</td>
<td>Prospective, multicenter</td>
<td>103</td>
<td>II</td>
<td>60</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 51 y; 97% Caucasian; 73% female</td>
<td>Subjects had high preoperative pain scores (mean [SD] of 81.5 [12.7]) and high levels of disability (ODI score 56.3 [12.1]). Duration of pain prior to enrollment averaged 5.7 y. EQ-5D at baseline was 0.45 (0.17), indicating a very poor QOL. 77% of subjects were taking opioids for back or SIJ pain preoperatively and 45% had a history of lumbar fusion, and concomitant spine and hip disease was common.</td>
<td>VAS pain scores at 5 y decreased by a mean of 54 points ODI decreased by 26 points EQOL-5D increased by 0.29 points</td>
<td>3 AEs were rated as device-related (1, intermittent hip and gluteal pain) and procedure-related (2, SI joint pain)</td>
</tr>
<tr>
<td>Darr and Cher 2018</td>
<td>Prospective, multicenter</td>
<td>103</td>
<td>II</td>
<td>48</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>NA</td>
<td>VAS pain scores in 91 subjects (88.3%) decreased by 54 points from baseline ODI decreased by 26 points EuroQOL-5D improved by 0.3 points</td>
<td>No new device- or procedure-related AEs during follow-up year 4</td>
<td>&lt;1% (1 subject underwent revision at year 3.8)</td>
</tr>
<tr>
<td>Darr et al 2018</td>
<td>Prospective, multicenter</td>
<td>103</td>
<td>II</td>
<td>36</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean (SD) preoperative SIJ pain score was 81.5 (12.6), and mean (SD) preoperative ODI was 56.3 (12.1)</td>
<td>At 3 y, VAS decreased to 26.2 (a 55-point improvement from baseline) and mean ODI was 28.2 (a 28-point improvement from baseline) EuroQOL-5D (EQ-5D) improved by 0.30 points</td>
<td>No new device- or procedure-related AEs during follow-up year 3</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Patel et al 2020</td>
<td>Prospective, multicenter</td>
<td>51</td>
<td>II</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean (SD) age: 53.2 y Female: 39 (76.5%)</td>
<td>Mean (SD) BMI: 31.3 (7.6)</td>
<td>Nonwhite race: 3 (5.9%) Hispanic: 2 (3.9%) ODI: 56.3</td>
<td>ODI decreased from 52.8 at baseline to 27.9 at 12 months.</td>
</tr>
<tr>
<td>Patel et al 2019</td>
<td>Prospective, multicenter</td>
<td>28</td>
<td>II</td>
<td>6</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 52 y (SD 15) Female: 23 (82%)</td>
<td>Mean BMI: 30.7 (SD 5.0)</td>
<td>Nonwhite race: 1 (3.6%) Hispanic: 2 (7.1%)</td>
<td>VAS decreased by 51 points and ODI decreased by 23.6 points</td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>Follow-Up, mo</td>
<td>Implant Type</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
<td>Revisions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duhon et al 2016&lt;sup&gt;136&lt;/sup&gt;</td>
<td>Prospective, multicenter, single-arm, clinical trial</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Average age: 50.9 y (96.5% Caucasian, 69.8% female) Baseline SIJ pain (mean 79.8 points, 0–100 scale) ODI, mean 55.2</td>
<td>VAS decreased from 79.8 at baseline to 26.0 at 24 mo ODI decreased from 55.2 at baseline to 30.9 at 24 mo</td>
<td>2.9% probably or definitely device-related 12.2% probably or definitely procedure-related</td>
<td>4.7% (8 of 172 patients)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Duhon et al 2016<sup>200</sup> | Prospective, multicenter, single-arm, clinical trial | 12 | iFuse | Lateral | No | Mean age: 50.9 y (96.5% Caucasian, 69.8% female) Baseline pain ratings (mean 79.8) and (ODI mean 55.2). Mean pain duration 5.1 y (0.43–41 y). 84.3% had pain for >1 y and 64.5% had pain for >2 y. | VAS improved from 79.8 at baseline to 30.0 and 30.4 at 6 and 12 mo, respectively (mean improvements of 49.9 and 49.1 points) Mean ODI improved from 55.2 at baseline to 32.5 and 31.4 at 6 and 12 mo (improvements of 22.7 and 23.9 points) SF-36 PCS improved from 31.7 at baseline to 60.6 at 6 and 12 mo Mean EQ-5D TTO index improved from 0.43 at baseline to 0.69 at 6 mo and 0.71 at 12 mo, increases of 0.25 and 0.27 points, respectively | 5 AEs related to device: 2 Neuropathy related to malposition: 1 SIJ pain after fall associated with inadequate device placement: 1 Hip pain related to periosteal bone growth around implant, 1 Mild buttock pain. 21 AEs related to procedure: 5 wound infection or drainage: 5 Buttocks or SIJ pain: 3 Postoperative nausea/vomiting: 2 Neuropathy related to malposition: 1 Staple irritation: 1 Numbness around Surgical wound: 1 Gluteal artery bleeding: 1 Urinary retention: 1 Fall causing SIJ pain: 4 cases (2.3%). |

<p>| Duhon et al 2013&lt;sup&gt;31&lt;/sup&gt; | Prospective, multicenter, single-arm, clinical trial | 6 | iFuse | Lateral | No | Mean age: 51 y (n = 94, safety cohort) 66% female Subjects were highly debilitated at baseline (mean VAS pain score 78, mean ODI score 54). | VAS improved from a baseline score of 76 ±16.2 to a 6-mo score of 29.3 ±23.3, an improvement of 49 points ODI improved from 55.3 ±10.7 to 38.9 ±15.8, an improvement of 15.5 points SF-36 PCS improved from 30.7 ±4.3 to 37.0 ±10.7, an improvement of 6.7 points EQ-5D TTO index improved from 0.43 at baseline to 0.65 at follow-up, a 23-point improvement. EQ-5D improved from 0.43 to 0.65 (an increase of 0 points) | 53 AEs occurred in 34 subjects | 0 revisions |</p>
<table>
<thead>
<tr>
<th>Author and Year</th>
<th>Study Design</th>
<th>N</th>
<th>Level of Evidence</th>
<th>Follow-Up, mo</th>
<th>Implant Type</th>
<th>BMP, DBM, Graft Used</th>
<th>Demographics</th>
<th>Results</th>
<th>Complications</th>
<th>Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capobianco et al 2015</td>
<td>Prospective, multicenter trial 12-mo results</td>
<td>172</td>
<td>II</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>52 males, 100 females without PPGP and 20 females had PPGP. PPGP subjects were significantly younger (43.3 y vs. 52.8 y for females without PPGP and 50.5 y for men.</td>
<td>Averaged VAS across 3 groups: 29.7 (31.4, 32.7, 25.0)</td>
<td>No complications reported</td>
<td></td>
</tr>
<tr>
<td>Cross et al 2018</td>
<td>Prospective multicenter</td>
<td>19</td>
<td>II</td>
<td>24</td>
<td>Threaded implant</td>
<td>Lateral</td>
<td>Mean age: 60.1 y, 35 female BMI: 29.1</td>
<td>VAS reduced to 2.2/10 12 mo postoperatively and 2.1/10 24 mo postoperatively 72% and 73% reduction in LBP, respectively. Reduction in LBP at both 12 and 24 mo, with large effect sizes of −3.5 and −2.9, respectively. At 12 months, 19/19 (100%) of patients met the MCID of ≥2/10 improvement on the NPS; at 24 mo follow-up 17.18 (94%) met the MCID.</td>
<td>No procedural complications, nor any device or procedure-related serious AEs</td>
<td>0 revisions</td>
</tr>
<tr>
<td>Kube and Muir 2016</td>
<td>Prospective</td>
<td>18</td>
<td>II</td>
<td>12</td>
<td>Threaded implant</td>
<td>Lateral</td>
<td>Mean age: 47.2 y (SD 14.2), Mean BMI: 29.4 (SD 5.3), 56% female</td>
<td>VAS back pain improved from 81.7 to 44.1 points and VAS leg pain from 63.6 to 27.7 points. ODI improved from 61.0 to 40.5 (P = 0.009).</td>
<td>4 procedural complications.</td>
<td>0 revisions</td>
</tr>
<tr>
<td>Rappoport et al 2017</td>
<td>Prospective</td>
<td>32</td>
<td>II</td>
<td>12</td>
<td>Hydroxyapatite-coated screw</td>
<td>Lateral</td>
<td>Mean age: 55.2 y, 62.5% female</td>
<td>VAS decreased from 55.8 mm preoperatively to 28.8 mm, 31.9 mm, and 32.7 mm, respectively, at 3, 6, and 12 mo postoperatively Mean ODI scores decreased from 55.6 to 53.3, 53.0, and 54.6, respectively, at 3, 6, and 12 mo postoperatively</td>
<td>No procedural complications</td>
<td>2 revisions</td>
</tr>
<tr>
<td>Araghi et al 2017</td>
<td>Prospective multicenter</td>
<td>50</td>
<td>II</td>
<td>6</td>
<td>Threaded implant</td>
<td>Lateral</td>
<td>Average age at baseline: 61.5 y, 58% female</td>
<td>VAS pain reduction at 6 mo from 76.2 at baseline to 35.1 Mean ODI improved from 55.5 to 53.5 at 6 mo</td>
<td>2 serious AEs reported for 2 patients</td>
<td>1 revision (2%)</td>
</tr>
<tr>
<td>Vanclocha et al 2018</td>
<td>Comparative case series with 6-y follow-up</td>
<td>137: 63 CM, 47 SI denervation, 27 SIJF</td>
<td>III</td>
<td>72</td>
<td>iFuse</td>
<td>Lateral</td>
<td>SIJF group (n = 27): Mean age: 48 y, Female: 19 BMI: 29.5</td>
<td>No SAES or procedural complications</td>
<td>0 revisions</td>
<td></td>
</tr>
<tr>
<td>Ledonio et al 2014</td>
<td>Retrospective study</td>
<td>44: 22 open, 22 MIS</td>
<td>III</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>MIS group only (n = 22): Average age 47.9 y, BMI: 30.5, 17 female</td>
<td>MIS group only: prep ODI, 61.5; postop ODI, 52.0</td>
<td>MIS group only: 3 complications</td>
<td>MIS group: 2 revisions</td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>Follow-Up (mo)</td>
<td>Implant Type</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
<td>Revisions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claus et al 2020</td>
<td>Retrospective review: comparison of patient-reported outcomes</td>
<td>12</td>
<td>Cylindrical threaded implants and iFuse</td>
<td>Allograft used</td>
<td>Average age: 58.4 y (33–82 y), 54 female (73%), Triangular dowel implant cohort: 82 patients; 73.2% female (60 patients)</td>
<td>Average both MIS VAS and ODI scores for Rialto and iFuse: VAS: −2.8, −2.4 and −2.6 from baseline 2.0, −2.4, −2.6 to 1.2, −1.5, −1.7, baseline 54.65 = 47.4 Rialto (n = 74), VAS back 2.8, 3.3, VAS leg: −1.7 (4.4), ODI −8.3 (14.9), SF-12 2.5 (5.7) iFuse: (n = 82) VAS back −2.4 (4.9), VAS leg −1.9 (4.6), ODI −6.2 (3.33), SF-12 −0.5 (9.9)</td>
<td>Complication rates have been seen as high as 16% in the iFuse system and as high as 52% in the CTI system. 6.1% revision rate in the CTI cohort was observed compared to a 2.4% revision rate in iFuse</td>
<td>6.1% revisions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rudolf 2012</td>
<td>Retrospective review: comparison of patient-reported outcomes</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Average age: 54 y (24–85 y), 34 female (68%), 16 male (32%), prior lumbar fusion: 22 (44%)</td>
<td>NRS 1–10 reported pain measures. Reported in reductions from baseline. QOL measures, but not ODI. Pain scores improved by an average of 5.9 points (n = 45)</td>
<td>10 peri-operative complications. 8% at 3 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ledonio et al 2014</td>
<td>Comparative retrospective chart review</td>
<td>12</td>
<td>3-hole reconstruction plate vs iFuse</td>
<td>Autograft used</td>
<td>39 patients (22 open, median age 66: 17 MIS, median age 51) who underwent SIJF with minimum 1-y follow-up</td>
<td>ODI scores improved significantly, from a median of 64 (44–78) to a median of 46 (10–80) in the open group and from a median of 53 (14–84) to a median of 13 (0–30) in the MIS group</td>
<td>VAS scores and ODI improved significantly directly after surgery from 84.3 ± 9.2 mm to 40.7 ± 9.2 mm and 19 from 76.8 ± 9.2% to 40.7 ± 9.2%. ODI improved further to 31 ± 5.4% after 24 mo, VAS 20 improved until the 3-mo examination and then stayed constant between 27.7 mm and 26.5 mm to 27 ± 6.6 mm at 24 mo</td>
<td>0 revisions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sachs and Capobianco 2012</td>
<td>Retrospective study</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>Autograft used</td>
<td>Average age: 65 y (45–82); 10 female (91%), 1 male (9%); prior lumbar spine surgery: 22 (44%)</td>
<td>Mean pain score at the 12-mo follow-up interval was 2.3 ± 5.1. Mean (SD) change in pain score was 5.4 ± 9.5 points</td>
<td>None</td>
<td>0 revisions</td>
<td></td>
</tr>
<tr>
<td>Bormann et al 2014</td>
<td>Retrospective 2-y</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 54.9 y (18–76 y), Male: 2; female: 22</td>
<td>VAS scores and ODI improved significantly directly after surgery from 83.4 ± 9.2 mm to 40.7 ± 9.2 mm and 19 from 76.8 ± 9.2% to 40.7 ± 9.2%. ODI improved further to 31 ± 5.4% after 24 mo, VAS 20 improved until the 3-mo examination and then stayed constant between 27.7 mm and 26.5 mm to 27 ± 6.6 mm at 24 mo</td>
<td>None</td>
<td>0 revisions</td>
<td></td>
</tr>
<tr>
<td>Bormann et al 2016</td>
<td>Retrospective 1-y</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 54.9 y (18–76 y), Male: 2; female: 22</td>
<td>ODI median decrease of 44 percentage points 57%</td>
<td>None</td>
<td>0 revisions</td>
<td></td>
</tr>
<tr>
<td>Rudolf 2013</td>
<td>Retrospective review</td>
<td>24</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 54 y NF: 18 (12 female, 6 male) PF: 11 female, 4 male LP: 7 (3 female, 4 male)</td>
<td>NRS scale mean change from baseline: NF cohort (n = 18) −584 (3.30), PF cohort (n = 15) −581 (3.50), LP cohort (n = 7) −4.79 (4.26)</td>
<td>8 peri-operative complications in 7 patients (17.5% complication rate; 3 from the NF cohort and 5 from the PF cohort) that all resolved without clinical sequelae</td>
<td>1 revision</td>
<td></td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>N</td>
<td>Level of Evidence</td>
<td>Follow-Up, mo</td>
<td>Implant Type</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
<td>Revisions</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>---</td>
<td>-------------------</td>
<td>---------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Al-Khayer et al 2008[30]</td>
<td>Retrospective, single center</td>
<td>9</td>
<td>IV</td>
<td>24</td>
<td>Hollow modular anchor, hollow screw</td>
<td>Lateral autograft</td>
<td>Average age: 42.4 y (35–56 y). Mean duration of symptoms before surgery: 30 mo (12–84 mo).</td>
<td>VAS dropped from 8.1 (7–9) preoperatively to 4.6 (3–7) postoperatively. Mean ODI dropped from 59 (34–70) preoperatively to 45 (28–60) postoperatively (P&lt;0.005). VAS pain scores from 8.6 improved by 6.1 points (5.7–6.6) to 2.7 points. Substantial clinical benefit, defined as a decrease in pain by 2.5 points or a score of 3.5 or less, was achieved in 91.9% of patients. VAS improved from 8.7 (1.5 SD) at baseline to 0.9 (1.6) at 12 mo, a 7.8-point improvement.</td>
<td>1 complication observed; a deep wound infection, which healed with debridement and intravenous antibiotics. 28 reported AEs, no intraoperative complications.</td>
<td>0 revisions</td>
</tr>
<tr>
<td>Sachs et al 2014[72]</td>
<td>Retrospective</td>
<td>144</td>
<td>IV</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral No</td>
<td>Mean age: 58 y 71% female 62% had a history of lumbar spinal fusion</td>
<td>Mean age: 58 y 71% female 62% had a history of lumbar spinal fusion</td>
<td>VAS pain scores from 8.6 improved by 6.1 points (5.7–6.6) to 2.7 points. Substantial clinical benefit, defined as a decrease in pain by 2.5 points or a score of 3.5 or less, was achieved in 91.9% of patients.</td>
<td>2 complications</td>
</tr>
<tr>
<td>Sachs 2013[78]</td>
<td>Retrospective</td>
<td>40</td>
<td>IV</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral No</td>
<td>Mean age: 58 y (30–81 y) 30 female, 10 male</td>
<td>Mean age: 58 y (30–81 y) 30 female, 10 male</td>
<td>VAS improved from 8.7 (1.5 SD) at baseline to 0.9 (1.6) at 12 mo, a 7.8-point improvement.</td>
<td>No intraoperative complications. 2 patients presented with trochanteric bursitis, 1 incident of piriformis syndrome 1 episode of new LBP</td>
</tr>
<tr>
<td>Sachs et al 2016[73]</td>
<td>Retrospective, multicenter 3.7-y follow-up</td>
<td>107</td>
<td>IV</td>
<td>44</td>
<td>iFuse</td>
<td>Lateral No</td>
<td>Mean age: 57.5 y (18–87 y) Mean BMI: 29.8 Years with SIJ pain: 5.9 y white 90.7%, black 5.6%, Hispanic 3.7%</td>
<td>Baseline to follow-up ODI 7.5 (1.7) to 2.6 (2.7), change score mean – 4.8 (2.9) Follow-up ODI score mean 28.2 (21.3)</td>
<td>No intraoperative complications, 5% complication rate.</td>
<td>4.7% (5 of 107 patients)</td>
</tr>
<tr>
<td>Cummings and Capobianco 2013[73]</td>
<td>Retrospective chart review</td>
<td>18</td>
<td>IV</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral No</td>
<td>Mean age: 64 y (39–81 y) Prima rily white (83%) and female (67%), 89% of patients in cohort were obese (BMI &gt; 30) or overweight (BMI 25–30), and 44 hyperensive. 83% had history of previous lumbar spine surgery that included fusion at 1 or more levels (73%), decompression (13%), and discectomy (13%).</td>
<td>VAS baseline mean 8.9 (SD 1.9), 12 mo 2.3 (SD 2.1). ODI baseline mean 52.7, 12 mo 13.2 (SD 12.6) SF-12 PCS 32.3 (SD 6.4), 12 mo 44.6 (SD 10.5). SF-12 MCS 37.6 (SD 10.2), 12 mo 53.8 (SD 9.5)</td>
<td>No intraoperative complications, 5% complication rate.</td>
<td>0 revisions</td>
</tr>
<tr>
<td>Gaetani et al 2013[73]</td>
<td>Retrospective chart review</td>
<td>12</td>
<td>IV</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral No</td>
<td>Mean age: 55.2 y (36–71 y).</td>
<td>Mean (±SD) ODI 31.4 (±6.3) preoperatively and 12 (±3.5) postoperatively QOL improved by 14.6 points from a baseline mean of 17.6 (±1) to 3 (±4.1) at follow-up. Mean preoperative VAS 7.7 (±1.3) and at follow-up improved by an average of 4.7 points for a mean follow-up score of 3 (±1.2)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>N</td>
<td>Level of Evidence</td>
<td>Follow-Up, mo</td>
<td>Implant Type</td>
<td>Technique</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>----</td>
<td>------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-----------</td>
<td>---------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------</td>
</tr>
<tr>
<td>Schroeder et al 2014</td>
<td>Retrospective</td>
<td>6</td>
<td>IV</td>
<td>10.25</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Average age: 50 y (25–60 y). The patients were 15.3 y on average after the original surgical procedure (range 4–25 y).</td>
<td>VAS score improved from 6.5 to 2.0; MCID 1.6</td>
<td>No complications</td>
</tr>
<tr>
<td>Cleveland et al 2019</td>
<td>Retrospective</td>
<td>50</td>
<td>IV</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>Mix of BMP, DBM, and autograft used</td>
<td>Average age: 51 y, 12 males, 38 females Average BMI: 20.2</td>
<td>VAS score improved from 7.83 to 2.67; MCID 1.6</td>
<td>Back VAS score decreased from 22.2 to 10.5; SRS-22 scores increased from 29.3 to 3.65</td>
</tr>
<tr>
<td>Rudolf and Capobianco 2014</td>
<td>Prospective</td>
<td>17</td>
<td>IV</td>
<td>60</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 58 y (36–85 y) 77% female 47% had prior lumbar spinal fusion</td>
<td>VAS score improved from 8.3 to 2.4 at 5 y 88% of patients reached substantial clinical benefit</td>
<td>No evidence of long-term complications, implant migration or loosening</td>
</tr>
<tr>
<td>Khurana et al 2009</td>
<td>Retrospective</td>
<td>15</td>
<td>IV</td>
<td>17</td>
<td>Hollow modular anchor hollow screw</td>
<td>No</td>
<td>No</td>
<td>Mean age: 48.7 y (37.3–62.6 y)</td>
<td>Mean SF-36 scores improved from 37 (23–51) to 80 (67–92) for physical function and from 55 (34–73) to 86 (70–98) for general health</td>
<td>Mean Majeed score improved from 37 (18–54) preoperatively to 79 (63–96) postoperatively</td>
</tr>
<tr>
<td>Smith et al 2013</td>
<td>Retrospective multcenter</td>
<td>263: 149 open, 114 MIS SIJF</td>
<td>IV</td>
<td>24</td>
<td>MIS only</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No graft used for TLI</td>
<td>MIS group only (n = 114): Mean age: 57.4 y 82 female 54 with prior lumbar fusion</td>
<td>VAS pain decreased from 8.0 to 2.5</td>
</tr>
<tr>
<td>Kandheria et al 2017</td>
<td>Retrospective analysis</td>
<td>45: 36 iFuse, 9 SAMBA screw</td>
<td>IV</td>
<td>32</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Average age: 52.7 y 82 male, 14 female</td>
<td>VAS: 4.0  ODI: 35.2</td>
<td>3 complications</td>
</tr>
<tr>
<td>Raino et al 2019</td>
<td>Retrospective case series</td>
<td>160</td>
<td>IV</td>
<td>12</td>
<td>iFuse</td>
<td>Lateral</td>
<td>No</td>
<td>Mean age: 58 y 68% female</td>
<td>VAS pain decreased from 8.0 to 2.5</td>
<td>ODI decreased from 45.3 to 16.4 Follow-up was obtained in 151 patients at 3 mo, 155 patients at 6 mo, 141 at 9 mo, and 90 at 12 mo</td>
</tr>
<tr>
<td>Author and Year</td>
<td>Study Design</td>
<td>N</td>
<td>Level of Evidence</td>
<td>Follow-Up, mo</td>
<td>Implant Type</td>
<td>BMP, DBM, Graft Used</td>
<td>Demographics</td>
<td>Results</td>
<td>Complications</td>
<td>Revisions</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------</td>
<td>---</td>
<td>------------------</td>
<td>--------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>--------------</td>
<td>--------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td>Rajpal and Burneikiene 2019</td>
<td>Retrospective review</td>
<td>24</td>
<td>Review article</td>
<td>19</td>
<td>Cylindrical threaded implants</td>
<td>Lateral</td>
<td>Allograft</td>
<td>Average age: 62.2 y, 3 males, 21 females</td>
<td>VAS reduction from an average baseline score of 6.6 to 3.7 postoperatively. Leg pain scores decreased from 4.8 to 1.5</td>
<td>2 patients had symptomatic subcutaneous hematomas, which resolved spontaneously, and 2 patients had superficial wound infections treated with antibiotics.</td>
</tr>
<tr>
<td>Dorsal/Posterior Endres and Ludwig 2013</td>
<td>Prospective</td>
<td>19</td>
<td>II</td>
<td>13.2</td>
<td>Threaded fusion cage</td>
<td>Posterior</td>
<td>Autograft</td>
<td>Mean age: 60.9 y (36–76 y)</td>
<td>VAS: 8.5 before surgery and 6 at final follow-up Mean ODI: 64.1 before surgery and 56.97 at final follow-up</td>
<td>No intraoperative complications.</td>
</tr>
<tr>
<td>Fuchs and Ruhl 2018</td>
<td>Prospective</td>
<td>171</td>
<td>II</td>
<td>24</td>
<td>Threaded fusion cage</td>
<td>Posterior</td>
<td>Allograft</td>
<td>At 24 mo: MVAS improved from 63% to 36%, ODI from 51% to 33%, SF-MPQ from 50% to 31%, VAS from 74 to 37. Radiographic fusion rate: 19% without BMP, 67% with BMP.</td>
<td>1 complication L5 radiculitis. 33% of cases had poor implant position (implant too far into sacrum or ilium)</td>
<td>1 revision</td>
</tr>
<tr>
<td>McGuire et al 2012</td>
<td>Retrospective case series</td>
<td>37</td>
<td>IV</td>
<td>40</td>
<td>Fibular dowel allograft</td>
<td>Posterior</td>
<td>Allograft</td>
<td>Mean age: 42.5 y (23–63) 34 females, 3 males</td>
<td>VAS score: 5.4 (94%) achieved clinical important difference at 6 mo and maintained through follow-up Fusion achieved: 34 (89.5%); nonunion: 4 (10.5%)</td>
<td>Nonunion occurred at 4 sites (10.5%). Each SJJ nonunion was successfully treated by secondary autogenous bone grafting and iliosacral compression screw fixation. There were no infections.</td>
</tr>
<tr>
<td>Wise and Dall 2008</td>
<td>Prospective</td>
<td>13</td>
<td>II</td>
<td>12</td>
<td>Threaded fusion cage</td>
<td>Posterior</td>
<td>No</td>
<td>Average age: 53.1 y (45–62 y) 12 females, 1 male</td>
<td>VAS back pain improved an average of 4.9 VAS leg pain improved an average of 2.4 Dispareunia improved by an average of 2.6</td>
<td>No infections or neurovascular complications.</td>
</tr>
</tbody>
</table>

Abbreviations: AE, adverse event; BMP, bone morphogenetic protein; CM, conservative management; CTI, Cylindrical Threaded Implant; DBM, Demineralized Bone Matrix; DSJQ, Denver Sacroiliac Joint Questionnaire, EQ-5D, Euroquol 5 dimension quality of life measure; LBP, low back pain; LP: patients with concomitant lumbar pathology treated non surgically; MCID, minimal clinically important difference; MIS indicates minimally invasive surgical; MVAS indicates Million Visual Analog Scale; SF-MPQ indicates Short Form McGill Pain Questionnaire; NF, patients with no history of spinal fusion or confounding lumbar pathology; ODI, Oswestry Disability Index; PCS, physical component summary; PF, patients with history of prior lumbar spinal fusion; PPGP, posterior pelvic girdle pain; QOL, quality of life; RCT, randomized controlled trial; SJ, sacroiliac joint; SJF, sacroiliac joint fusion; TDI, Triangular Dowel Implant; TTO, time trade-off index; VAS, visual analog score.

*Not FDA cleared for SJF.*

Initial search was tested for inclusiveness (as wide a net as possible) against Lorio 2016 ISASS update list of articles. Search terms captured all articles in Lorio 2016 table.

Non-English and non-human articles removed

Articles unrelated to MIS SI joint fusion but shared some search terms were categorized and removed. Anatomy, Biomechanics, Cadaver, Spine only, Pediatric, Imaging only, Oncology, Infection, Genetics, Pre-2000, etc.

Removed all articles that do not have as results patient-reported outcomes, VAS and ODI, SF-36, and EQ-5D. See Table 2 for 48 articles remaining.